fulvestrant has been researched along with benzyloxycarbonylleucyl-leucyl-leucine aldehyde in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Bermont, L; Boubekeur, K; Cleeren, A; Jacquot, Y; Laïos, I; Laurent, G; Leclercq, G; Nonclercq, D; Refouvelet, B; Xicluna, A | 1 |
| Dong, C; Hu, Z; Huang, J; Huang, Y; Li, Y; Ning, W; Xiao, Y; Xie, B; Zhao, C; Zhou, HB | 1 |
| Dutertre, M; Mancini, MA; Mancini, MG; O'Malley, BW; Patel, K; Smith, CL; Stenoien, DL | 1 |
| Bell, DW; Coser, KR; Dean, KL; Hilario, PC; Hur, J; Isselbacher, KJ; Okimoto, RA; Shioda, T; Smith, SL; Tobey, EM | 1 |
| Kang, L; Wang, ZY | 1 |
| Marks, JR; McDonnell, DP; Wardell, SE | 1 |
| Basile, I; Gallud, A; Garcia, M; Gary-Bobo, M; Maynadier, M | 1 |
8 other study(ies) available for fulvestrant and benzyloxycarbonylleucyl-leucyl-leucine aldehyde
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Synthesis, structure, and estrogenic activity of 4-amino-3-(2-methylbenzyl)coumarins on human breast carcinoma cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Coumarins; Estrogens; Humans; Ligands; Luciferases; Models, Molecular; Molecular Structure; Promoter Regions, Genetic; Receptors, Estrogen; Thymidine Kinase; Transcription, Genetic; Transcriptional Activation; Tumor Cells, Cultured | 2007 |
Novel class of 7-Oxabicyclo[2.2.1]heptene sulfonamides with long alkyl chains displaying improved estrogen receptor α degradation activity.
Topics: Apoptosis; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Estrogen Antagonists; Estrogen Receptor alpha; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Structure-Activity Relationship; Sulfonamides; Tumor Cells, Cultured | 2019 |
FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent.
Topics: Bacterial Proteins; Biological Transport; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Dactinomycin; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; HeLa Cells; Histone Acetyltransferases; Humans; Leupeptins; Ligands; Luminescent Proteins; Microscopy, Fluorescence; Multienzyme Complexes; Nuclear Matrix; Nuclear Receptor Coactivator 1; Proteasome Endopeptidase Complex; Protein Structure, Tertiary; Receptors, Estrogen; Tamoxifen; Transcription Factors; Transcription, Genetic | 2001 |
Regulation of expression of BIK proapoptotic protein in human breast cancer cells: p53-dependent induction of BIK mRNA by fulvestrant and proteasomal degradation of BIK protein.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis Regulatory Proteins; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Estradiol; Fulvestrant; Gamma Rays; Gene Expression Regulation, Neoplastic; Humans; Leupeptins; Membrane Proteins; Mitochondrial Proteins; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Receptors, Estrogen; RNA, Messenger; Transcription, Genetic; Tumor Suppressor Protein p53 | 2006 |
Breast cancer cell growth inhibition by phenethyl isothiocyanate is associated with down-regulation of oestrogen receptor-alpha36.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Female; Fulvestrant; Genome, Human; Humans; Isothiocyanates; Leupeptins; Phosphorylation; Signal Transduction | 2010 |
The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy.
Topics: Cells, Cultured; Estradiol; Estrogen Antagonists; Estrogen Receptor alpha; Fulvestrant; Humans; Insulin-Like Growth Factor I; Leupeptins | 2011 |
Combination treatment with proteasome inhibitors and antiestrogens has a synergistic effect mediated by p21WAF1 in estrogen receptor-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Breast Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinases; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Humans; Leupeptins; MCF-7 Cells; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Raloxifene Hydrochloride; Receptors, Estrogen; RNA, Messenger; Tamoxifen | 2016 |